SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 22.57 |
| Enterprise Value ($M) | -34.07 |
| Book Value ($M) | 5.67 |
| Book Value / Share | 0.47 |
| Price / Book | 3.98 |
| NCAV ($M) | -8.04 |
| NCAV / Share | -0.66 |
| Price / NCAV | -2.80 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.44 |
| Return on Assets (ROA) | -0.31 |
| Return on Equity (ROE) | -0.98 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.51 |
| Current Ratio | 7.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 78.61 |
| Assets | 92.33 |
| Liabilities | 86.66 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -66.10 |
| Net Income | -47.73 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -67.72 |
| Cash from Investing | 19.93 |
| Cash from Financing | 95.14 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Sio Capital Management, LLC | 0.00 | -100.00 | |
| 13G/A | Bristol Myers Squibb Co | 1.64 | -73.62 | |
| 13G/A | 5AM Ventures IV, L.P. | 0.00 | ||
| 13G/A | Temasek Holdings (Private) Ltd | 2.60 | ||
| 13G/A | ARCH Venture Fund VIII, L.P. | |||
| 13D | Acorn Bioventures, L.p. | 6.70 | ||
| 13D | Atlas Venture Fund X, L.P. | 7.20 | ||
| 13G | Carlyle Group Inc. | 9.20 | ||
| 13D | Orbimed Advisors Llc | 18.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 38,194 | 106,016 | 36.03 | |
| 33,841 | 89,462 | 37.83 | |
| 39,303 | 86,964 | 45.19 | |
| 66,735 | 231,724 | 28.80 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PTPI – Petros Pharmaceuticals, Inc. | PULM – Pulmatrix, Inc. |
| QLGN – Qualigen Therapeutics, Inc. | RENB – Renovaro Inc. |
| REVB – Revelation Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io